RecruitingPriority 4 · Lower priorityNCT07132567
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Plain-language summary
This trial is studying Poteligeo 20mg for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 19 Years or older
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Poteligeo 20mg (DRUG): Poteligeo 20mg
- Drugs / treatments
- Poteligeo 20mg
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details